RayzeBio has raised $45 million in a round of series A financing to advance the development of its targeted radiopharmaceuticals for cancer therapies.
The funds will be used to advance the company's pipeline of drugs against validated cancer targets and focus on delivering the alpha-emitting radioisotope actinium-225. The investors are venBio Partners, Versant Ventures, and Samsara BioCapital.